Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura C Coates

Showing results (141-150 of 342) with videos related to

Pageof 35
Sort By:
RMD Open|March 5, 2022
Gender equity in academic rheumatology: is there a gender gap at European rheumatology conferences?Neelam Hassan, Leonieke Jj van Mens, Uta Kiltz, et al.
The Journal of Rheumatology|May 3, 2017
International Treatment Recommendations Update: A Report from the GRAPPA 2016 Annual MeetingLaura C Coates, Vinod Chandran, Alexis Ogdie, et al.
RMD Open|July 19, 2022
Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trialXenofon Baraliakos, Effie Pournara, Laure Gossec, et al.
Annals of the Rheumatic Diseases|October 30, 2017
Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohortLeonieke J J van Mens, Marleen G H van de Sande, Arno W R van Kuijk, et al.
RMD Open|October 1, 2019
Measurement properties of the minimal disease activity criteria for psoriatic arthritisLaura C Coates, Vibeke Strand, Hilary Wilson, et al.
The Lancet. Rheumatology|June 8, 2026
Silent patients, silent disease: misalignment in patient-initiated follow-upAlice E Jennings, Ailsa Bosworth, Mel Brooke, et al.
Annals of the Rheumatic Diseases|March 30, 2025
Diagnostic delay and less intensive therapy for people with psoriatic arthritis compared with rheumatoid arthritis: a study nested within an English and Welsh audit data setRachel A Charlton, Emer Gates, Laura C Coates, et al.
Therapeutic Advances in Musculoskeletal Disease|June 3, 2024
The protocol of a clinical effectiveness trial comparing standard step-up care, early combination DMARD therapy and early use of TNF inhibitors for the treatment of moderate to severe psoriatic arthritis: the 3-arm parallel group SPEED randomized controlled trialMarion Watson, William Tillett, Deepak Jadon, et al.
Arthritis Research & Therapy|February 10, 2022
Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placeboDafna D Gladman, Laura C Coates, Joseph Wu, et al.
Arthritis Research & Therapy|March 26, 2021
Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinibLaura C Coates, Andrew G Bushmakin, Oliver FitzGerald, et al.
Pageof 35

Showing results (141-150 of 342) with videos related to

Sort By:
Pageof 35
RMD Open|March 5, 2022
Gender equity in academic rheumatology: is there a gender gap at European rheumatology conferences?Neelam Hassan, Leonieke Jj van Mens, Uta Kiltz, et al.
The Journal of Rheumatology|May 3, 2017
International Treatment Recommendations Update: A Report from the GRAPPA 2016 Annual MeetingLaura C Coates, Vinod Chandran, Alexis Ogdie, et al.
RMD Open|July 19, 2022
Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trialXenofon Baraliakos, Effie Pournara, Laure Gossec, et al.
Annals of the Rheumatic Diseases|October 30, 2017
Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohortLeonieke J J van Mens, Marleen G H van de Sande, Arno W R van Kuijk, et al.
RMD Open|October 1, 2019
Measurement properties of the minimal disease activity criteria for psoriatic arthritisLaura C Coates, Vibeke Strand, Hilary Wilson, et al.
The Lancet. Rheumatology|June 8, 2026
Silent patients, silent disease: misalignment in patient-initiated follow-upAlice E Jennings, Ailsa Bosworth, Mel Brooke, et al.
Annals of the Rheumatic Diseases|March 30, 2025
Diagnostic delay and less intensive therapy for people with psoriatic arthritis compared with rheumatoid arthritis: a study nested within an English and Welsh audit data setRachel A Charlton, Emer Gates, Laura C Coates, et al.
Therapeutic Advances in Musculoskeletal Disease|June 3, 2024
The protocol of a clinical effectiveness trial comparing standard step-up care, early combination DMARD therapy and early use of TNF inhibitors for the treatment of moderate to severe psoriatic arthritis: the 3-arm parallel group SPEED randomized controlled trialMarion Watson, William Tillett, Deepak Jadon, et al.
Arthritis Research & Therapy|February 10, 2022
Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placeboDafna D Gladman, Laura C Coates, Joseph Wu, et al.
Arthritis Research & Therapy|March 26, 2021
Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinibLaura C Coates, Andrew G Bushmakin, Oliver FitzGerald, et al.
Pageof 35